ストックスクリーナーアプリを入手
109.93
0.43%
0.47
プレマーケット:
110.37
0.44
+0.40%
前日終値:
$109.46
開ける：
$109.69
24時間の取引高:
1.61M
Relative Volume:
0.68
時価総額：
$217.12B
収益：
$51.72B
当期純損益:
$11.94B
株価収益率:
18.70
EPS:
5.88
ネットキャッシュフロー:
$13.81B
1週間 パフォーマンス:
+7.82%
1か月 パフォーマンス:
+0.80%
6か月 パフォーマンス:
-5.41%
1年 パフォーマンス:
+16.44%
1日の値動き範囲:
$109.29
$110.53
1週間の範囲:
$97.72
$110.53
52週間の値動き範囲:
$92.35
$120.92
Novartis Ag Adr Stock (NVS) Company Profile
NVS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
109.93 | 217.12B | 51.72B | 11.94B | 13.81B | 5.88 |
|
LLY
Lilly Eli Co
|
757.18 | 680.08B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
153.62 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
ABBV
Abbvie Inc
|
176.80 | 312.76B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
64.49 | 286.27B | 42.09B | 14.65B | 10.11B | 3.2833 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-13 | ダウングレード | UBS | Buy → Neutral |
| 2025-02-12 | 開始されました | Morgan Stanley | Underweight |
| 2025-02-04 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-12-04 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2024-09-11 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-09-05 | ダウングレード | Goldman | Buy → Neutral |
| 2024-09-03 | ダウングレード | Jefferies | Buy → Hold |
| 2024-07-19 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-02-23 | 開始されました | BMO Capital Markets | Market Perform |
| 2024-01-23 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 再開されました | UBS | Buy |
| 2023-12-18 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-09-25 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-04-26 | アップグレード | Deutsche Bank | Hold → Buy |
| 2023-03-27 | アップグレード | Deutsche Bank | Sell → Hold |
| 2023-01-26 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-12-05 | アップグレード | Stifel | Hold → Buy |
| 2022-09-15 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2022-09-14 | ダウングレード | Berenberg | Buy → Hold |
| 2022-05-09 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2022-01-10 | 再開されました | Citigroup | Buy |
| 2021-12-14 | ダウングレード | Redburn | Buy → Neutral |
| 2021-12-06 | ダウングレード | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-03 | ダウングレード | Bryan Garnier | Buy → Neutral |
| 2021-09-20 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2021-03-22 | 開始されました | Bernstein | Mkt Perform |
| 2021-03-10 | ダウングレード | Argus | Buy → Hold |
| 2021-02-01 | ダウングレード | Cowen | Outperform → Market Perform |
| 2021-01-15 | 開始されました | Deutsche Bank | Buy |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2020-09-10 | アップグレード | UBS | Neutral → Buy |
| 2020-09-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-15 | アップグレード | Citigroup | Neutral → Buy |
| 2020-03-10 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-25 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-04-25 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-04-25 | アップグレード | Liberum | Hold → Buy |
| 2019-04-10 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2019-01-02 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-12-11 | 再開されました | Jefferies | Buy |
| 2018-10-09 | 開始されました | Guggenheim | Neutral |
| 2018-09-10 | アップグレード | BofA/Merrill | Underperform → Buy |
| 2018-05-29 | ダウングレード | HSBC Securities | Buy → Hold |
| 2018-05-25 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-01-25 | 繰り返されました | Leerink Partners | Outperform |
| 2017-12-06 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2017-07-26 | アップグレード | Morgan Stanley | Underweight → Overweight |
| 2017-07-05 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2017-03-09 | 開始されました | Liberum | Buy |
すべてを表示
Novartis Ag Adr (NVS) 最新ニュース
Swiss pharmaceutical giant announces plans for $1.1B campus in San Diego - fox5sandiego.com
Novartis Commits $23 Billion To Expand US Manufacturing Over Five Years, Despite Tariffs Uncertainties - Benzinga
Pharma Stock Roundup: FDA Nod To SNY, AZN & NVS, JNJ Talc Suits Failure - Barchart.com
FDA Grants Accelerated Approval To NVS Kidney Disease Drug - Barchart.com
Quantum Corp’s Banking’s 100-Day Moving Average at 21.57: Will the Stock Break Through? - investchronicle.com
Novartis Holds a Strong Branded Drug Portfolio Supporting Steady Long-Term Growth - Morningstar
No room on the ARK? - Morningstar.com.au
5 Large Drug Stocks To Watch As Industry Recovers - Barchart
FDA Approves Novartis Drug For Rare Kidney Disease Treatment - Barchart
Novartis scraps use of diverse panels for hires in US - Reuters
Alnylam Rallies 62% In A Year: Can The Stock Maintain This Momentum? - Barchart
Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - GlobeNewswire Inc.
Complement C4 Antibody Market Research 2025: Growing Focus on Precision Medicine and Targeted Therapies, and Increasing Investment in Immunotherapies and Biologic Drugs - GlobeNewswire Inc.
Alberta sets a new standard for advanced prostate cancer treatment with public reimbursement of Pluvicto™ - Barchart
Giovanni Caforio, M.D. - Novartis
Novartis Near Buy Point; Earns Near-Best Overall Rating - Investor's Business Daily
META_TITLE_QUOTE - Yahoo Finance
Novartis Earnings Surprised The Street; Still Going Strong - Investor's Business Daily
Novartis Gets CHMP Opinion for Label Expansion of Fabhalta - Yahoo Finance
AZN: 3 AI-Powered Drug Discovery Stocks Revolutionizing Medicine - StockNews.com
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
NVS: 3 Gene Therapy Stocks With Game-Changing Potential - StockNews.com
NVS Quantitative Stock Analysis - Nasdaq
Novartis: Strong Execution With A P/E Discount (NYSE:NVS) - Seeking Alpha
Company’s Banking Stock: Dissecting a 2.21% Quarterly Revenue Decline Amid Growth - The InvestChronicle
Novartis receives Health Canada approval for Fabhalta® oral treatment for adult patients with PNH - Barchart
Novartis to buy Anthos Therapeutics in $3.1bn deal - Proactive Investors UK
Novartis to buy Anthos Therapeutics in $3.1bn deal | NYSE:NVS - Proactive financial news
Novartis 2017 Financial Results - Novartis
ATI Inc [ATI] Records 200-Day SMA of $59.51 - Knox Daily
Taking a look at what insiders are doing to gauge the America Movil S.A.B.DE C.V. ADR (AMX)’s direction - Knox Daily
Novartis AG ADR [NVS] Officer makes an insider purchase of 6,566 shares worth 0.73 million. - Knox Daily
NVS’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Novartis AG ADR (NVS) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Novartis AG ADR [NVS] is 12.85% higher this YTD. Is it still time to buy? - The DBT News
Delhi High Court grants ad interim injunction to leading pharmaceutical company NOVARTIS; restrains use of NOVITAS mark - SCC Online
HSBC Securities downgrades Novartis AG ADR (NVS) rating to a Reduce - Knox Daily
2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond - sharewise
Novartis's SWOT analysis: pharma giant's stock navigates generic headwinds - Investing.com
Novartis Earnings: Results In-Line; Growth Brands to Offset Entresto Loss of Exclusivity in 2025 - Morningstar
Novartis Financial Results – Q1 2021 - Novartis
Novartis 2016 Financial Results - Novartis
Novartis Financial Results – Q2 2023 - Novartis
Novartis Ag Adr (NVS) 財務データ
収益
当期純利益
現金流量
EPS
0.99%
0.47%
大文字化:
|
ボリューム (24 時間):